Immunis® Cytokeratin 18F EIA *Available in Japan only
Immunis® Cytokeratin 18F EIA
In Vitro Diaginostic Reagent in Japan
Cytokeratin 18 fragment (CK-18F) is a marker associated with apoptosis¹; tests using this kit have shown that CK-18F levels are higher in non-alcoholic steatohepatitis (NASH) than in non-alcoholic fatty liver disease (NAFL)².
“Immunis® Cytokeratin 18F EIA” is a reagent based on the enzyme-linked immunosorbent assay (ELISA) method for measuring CK-18F in serum. It is used as an aid in the diagnosis of NASH by combining it with fibrosis markers. This kit is expected to enable the non-invasive and convenient screening of NASH cases that require a liver biopsy.
- Purpose Measuring human cytokeratin 18 fragment (CK-18F) in serum (as an aid in the diagnosis of non-alcoholic steatohepatitis (NASH))
-
Features
Diagnostic reagent used to aid in the diagnosis of NASH, based on a one-step sandwich enzyme-linked immunosorbent assay (EIA)
Effective for identifying high-risk cases of NASH, as it reflects ballooning degeneration, one of the hallmarks of NASH, and the NAFLD Activity Score (NAS), a pathological indicator of disease activity
Reaction time: 1.5 hours - Product Name Immunis® Cytokeratin 18F EIA
-
Product Code / Package
1A91
96 tests - JAN Code 4987591012079
-
References
1. Strnad P, et al: Keratins: markers and modulators of liver disease. Curr Opin Gastroenterol 28: 209-216, 2012.
2. Leers MPG, et al: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572, 1999.
3. Wieckowska A, et al: In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33, 2006.
4. Yilmaz Y, et al: Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 13: 837-844, 2007.
5. Diab DL, et al: Cytokeratin 18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 6: 1249-1254, 2008.
6. Feldstein AE, et al: Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multi-center validation study. Hepatology 50: 1072-1077, 2009.
7. Musso G, et al: Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:617-649, 2011.